Verapamil vs Steroid to Prevent Keloid Recurrence

• Status: Terminated
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Keloid scarring is a severe cosmetic and painful disease of the skin. The gold standard treatment is yet to be clarified. This randomized clinical pilot study will compare the effects of two local treatments for preventing keloid recurrence after surgical removal; steroid and verapamil.

Study hypothesis: Intralesional therapy with the calcium antagonist verapamil has equal treatment efficacy as steroid injection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Western Australia
• Treatments: Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide; Verapamil

Criteria

Inclusion Criteria:

• Patient undergoing surgical removal of keloid

• Patient 18 years old or greater

• Length of excisional scar after surgical removal of keloid between 2 and 10 cm

Exclusion Criteria:

• Keloid in face or hands

• Pregnancy or lactation

• Dementia

• Any heart or pulmonary condition

• Systemic treatment with beta-blockers, ACE-inhibitors or calcium antagonists

• Systemic corticosteroidal therapy

• Intralesional steroid treatment within 2 months of surgery to remove keloid

• Flap surgery

• Lesions to face, hands and other cosmetically sensitive areas